Roche (RHHBY.PK) abandons efforts to move the heart drug dalcetrapib to market, following poor...


Roche (RHHBY.PK) abandons efforts to move the heart drug dalcetrapib to market, following poor results from a late stage study. The move follows a similar failure last week by Pfizer (PFE) in the category, and analysts predict negative sentiment towards other such drugs in trials, such as Merck’s (MRK) anacetrapib and Eli Lilly’s (LLY) evacetrapib. MRK -0.8%, LLY -0.7% premarket.

From other sites
Comments (4)
  • bernie 1
    , contributor
    Comments (674) | Send Message
     
    Whenever I read about a Pharma. abandoning a drug in late stage trials I think of all those people who will not be helped. I also think of the politicians & the ones who don't have a clue who talk about how much money the companies make on successful drugs,but forget or don't know the cost of giving up on a drug trial after 10 or even 12 years. Being a pharma can be lucrative but having failures are also a part of the profit stream.
    Bernie 1
    7 May 2012, 09:24 AM Reply Like
  • KAGLAR
    , contributor
    Comments (3) | Send Message
     
    I don't see any conditions that these drugs were supposed to help, or why they were abandoned
    7 May 2012, 05:38 PM Reply Like
  • KAGLAR
    , contributor
    Comments (3) | Send Message
     
    I am a retired, individual investor. I don't invest "day trader" style, but I am probably not your average "buy and hold" investor either.
    7 May 2012, 05:44 PM Reply Like
  • william1
    , contributor
    Comment (1) | Send Message
     
    With 4 major companies researching this class of compounds and not marketing them tells me that there are basic flaws with that class of compounds. it's too bad these won't be around to help some people. As a retired sales rep for one of the 4 companies, I know 1st hand how frustrating and expensive these failures are.
    7 May 2012, 06:19 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs